Psoriasis News and Research

Latest Psoriasis News and Research

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

avVaa World Health Care Products Inc. a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the launch of its two week Neuroskin(R) Psoriasis Relief DRTV media test campaign.

5 Oct 2009

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

Two-thirds of women say psoriasis negatively affects their overall emotional well-being

Women with psoriasis and psoriatic arthritis are markedly more likely than men to suffer from the emotional and psychological effects of the diseases, according to survey data released by the National Psoriasis Foundation today.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

Welichem announces filing of clinical trial application with Health Canada

Welichem Biotech Inc. (the "Company") announces the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded clinical trial in patients with chronic atopic dermatitis at three trial centres.

1 Oct 2009

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

Stelara approved by the FDA for treating psoriasis

The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis.

25 Sep 2009

$4.5 million cost involved for MLSIC set up

The Michigan Economic Development Corp. (MEDC), Ann Arbor SPARK, Greater Wayne Economic Development Corporation and a private foundation have collaborated to create the Michigan Life Science and Innovation Center (MLSIC). MLSIC will connect well-funded, experienced entrepreneurs with business accelerator organizations and start-up life science companies.

25 Sep 2009

Symposium on genetics of psoriasis and psoriatic arthritis to be held

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

24 Sep 2009

NIHR to fund patient panel for skin disease research

People who suffer from skin disease are being asked to help make research more effective by joining a new 'Patient Panel'.

24 Sep 2009

LEO Pharma re-acquires product licensing rights from Warner Chilcott

Warner Chilcott plc (Nasdaq: WCRX) and LEO Pharma announced today that, in exchange for a one-time cash payment of $1.0 billion to Warner Chilcott, LEO Pharma is re-acquiring Warner Chilcott's exclusive product licensing rights in the United States to its topical psoriasis treatments Taclonex(R), Taclonex Scalp(R), Dovonex(R) as well as rights to all products in LEO's development pipeline, and acquiring all inventories of the products.

24 Sep 2009

Comprehensive and practical overview of psoriasis

Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases).

22 Sep 2009

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Nasdaq Stock Market issues noncompliance notice to PhotoMedex

PhotoMedex, Inc. (Nasdaq:PHMD) (the “Company”) announced today that it received notification from The Nasdaq Stock Market (“Nasdaq”) on September 15, 2009 that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq’s Global Market exchange under Nasdaq Marketplace Rule 4450(a)(5) (the “Rule”).

19 Sep 2009

Resolvyx Pharmaceuticals receives U.S. patent for RX-10045

Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.

19 Sep 2009

Updated financial information released by avVaa World Health

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the release of updated financial information.

19 Sep 2009

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

PhotoMedex, Inc., a leading provider of advanced dermatology, clinical skincare and medical laser products, today announced Neova DNA Repair Factor Nourishing Lotion, the newest addition to its renowned Neova brand of skin and hair products.

16 Sep 2009